Copyright ©The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Hepatol. Aug 27, 2020; 12(8): 506-518
Published online Aug 27, 2020. doi: 10.4254/wjh.v12.i8.506
Racial disparities in nonalcoholic fatty liver disease clinical trial enrollment: A systematic review and meta-analysis
Parita Patel, Charles Muller, Sonali Paul
Parita Patel, Charles Muller, Sonali Paul, Section of Gastroenterology, Hepatology, and Nutrition, University of Chicago Medical Center, Chicago, IL 60637, United States
Author contributions: Patel P and Muller C contributed to this manuscript equally; Paul S designed the study; Patel P and Muller C collected clinical data; Muller C conducted statistical analysis; Patel P, Muller C, and Paul S prepared and approved the final version of the manuscript.
Conflict-of-interest statement: The authors deny any conflict of interest.
PRISMA 2009 Checklist statement: The authors have read the PRISMA 2009 Checklist, and the manuscript was prepared and revised according to the PRISMA 2009 Checklist.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See:
Corresponding author: Sonali Paul, MD, MSc, Assistant Professor, Section of Gastroenterology, Hepatology, and Nutrition, University of Chicago Medical Center, 5841 S Maryland Avenue, MC 4076, Chicago, IL 60637, United States.
Received: April 13, 2020
Peer-review started: April 13, 2020
First decision: April 29, 2020
Revised: July 9, 2020
Accepted: July 26, 2020
Article in press: July 26, 2020
Published online: August 27, 2020
Core Tip

Core tip: The Hispanic population in the United States is disproportionately affected by non-alcoholic fatty liver disease (NAFLD). Currently, there is no Food and Drug Administration approved treatment for this disease, but several clinical trials are investigating new potential therapies. This study evaluates the inclusion of race and ethnicity in the enrollment of these trials. In a systemic review and meta-analysis of clinical trials for treatment of NAFLD, 44% of eligible trials reported data on race and ethnicity. Despite a high burden of disease, Hispanic participation remained low. Future targeted interventions must take place to increase the enrollment of diverse and representative study populations in clinical trials.